<DOC>
	<DOCNO>NCT00782535</DOCNO>
	<brief_summary>The purpose study characterize dose-response profile peak trough FEV1 single dose administration carmoterol patient COPD .</brief_summary>
	<brief_title>Safety Efficacy Study Treatment With Single Doses CHF 4226 pMDI Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Patient sign IRB approve Informed Consent form write informed consent obtain prior studyrelated procedure ( ) Patient male nonpregnant female , 40 75 year old , inclusive Patient current past cigarette smoke history least 15 packyears Patient clinical diagnosis COPD accordance recommendation National Heart Lung Blood Institute/World Health Organization ( NHLBI/WHO ) Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Patient meet follow requirement FEV1 albuterol reversibility test ( i.e. , 30 minute follow 400µg ( meter dose ) albuterol MDI ) : FEV1/FVC &lt; 70 % FEV1 least 0.9L FEV1 30 % 80 % , inclusive , patient 's predict normal value ∆FEV1 &gt; 5 % prealbuterol value If ∆FEV1 &lt; /= 5 % prealbuterol value , requirement must meet retesting runin period , least 24 hour prior Visit 2 . Patient history asthma Patient blood eosinophil count &gt; 500/µL Patient history allergic rhinitis atopy Patient COPD exacerbation lower respiratory tract infection within 8 week prior screen , runin period , result use antibiotic , oral parenteral corticosteroid Patient inhale corticosteroid initiate , effective dose change , within 4 week prior screen runin period Patient uncontrolled cardiovascular ( e.g. , uncontrolled hypertension ) , respiratory , hematologic , immunologic , renal , neurologic , hepatic , endocrine ( e.g. , uncontrolled diabetes mellitus ) disease , condition might , judgment Investigator , place patient undue risk potentially compromise result interpretation study Patient clinically significant abnormal routine hematology ( e.g. , anemia ) and/or clinical chemistry value ( ) . Patient history coronary artery disease , cerebrovascular disease , cardiac arrhythmia Patient lung cancer history lung cancer Patient active cancer history cancer le 5 year disease free survival time ( whether evidence local recurrence metastasis ) . Localized basal cell carcinoma ( without metastasis ) skin acceptable . Patient serum potassium value ≤ 3.5 mEq/L &gt; 5.5mEq/L and/or fast serum glucose value ≥ 140 mg/dL Patient abnormal QTcF interval value Screening visit ECG test ( i.e. , &gt; 450 msec male &gt; 470 msec female ) Patient develop Cor Pulmonale Patient receive long term oxygen therapy , i.e. , &gt; 16 hours/24hour period , every day , unless reside elevation &gt; 4000ft Patient use follow medication prior Screening meet specified minimum washout period : Long act anticholinergic agent ( i.e. , tiotropium ) : 7 day Short act anticholinergic : 8 hour Fixed combination β2agonists inhale corticosteroid : 48 hour Fixed combination anticholinergic short act β2agonist : 8 hour Longacting β2agonists : 48 hour Short act β2agonists : 6 hour Theophylline xanthine : 1 week Parenteral oral corticosteroid : 1 month Patient take nonpermitted medication Patient receive liveattenuated virus vaccination within two week prior screen runin ( inactivated Influenza vaccination acceptable provide administer within 48 hour prior Screening ) Patient know intolerance/hypersensitivity β2adrenergic agonist , propellant gases/excipients Patient pregnant lactate female , female physiologically capable become pregnant UNLESS meet follow definition postmenopausal : 12 month natural ( spontaneous ) amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL OR use one follow acceptable method contraception : surgical sterilization ( e.g. , bilateral tubal ligation , hysterectomy ) hormonal contraception ( implantable , patch , oral ) doublebarrier method ( double combination : IUD , male female condom spermicidal gel , diaphragm , sponge , cervical cap ) Patient male agree use medically acceptable contraceptive ( abstain sexual intercourse , use condom spermicide ) , vasectomy least 6 month prior study participation , unless sexual partner childbearing potential Patient mentally legally incapacitated Patient participate another investigational study within 30 day prior screen Patient abuse alcohol substance Patient maintain regular day/night , waking/sleeping cycle ( e.g. , night shift worker ) Patient potentially noncompliant unable perform require outcome measurement protocol</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>